Covax was established by public health agencies, including the World Health Organization, to provide governments with early access to a large portfolio of COVID-19 vaccines.

The vaccine will be manufactured and distributed globally by Novavax and the Serum Institute of India (SII). Novavax licensed its vaccine to SII with no upfront, milestone, or technology transfer payments. Novavax and SII are jointly committed to deliver 1.1 billion doses to the Covax facility.

Gavi will work with Novavax to finalize an advance purchase agreement for vaccine supply and global distribution allocation via the Covax facility and its partners.

The company also announced that it has completed enrollment of its Prevent-19 phase III study in the U.S. and Mexico to evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373. The study has enrolled 30,000 individuals from diverse populations. Two-thirds of the participants are assigned to randomly receive two intramuscular injections of the vaccine, administered 21 days apart, while one-third of the trial participants receive a placebo. Prevent-19 is being conducted with support from the U.S. government partnership.

SK Bioscience to supply Novavax COVID-19 vaccine to millions in Korea
SK Bioscience is set to supply the Korean government with 40 million doses of Novavax's COVID-19 vaccine through a new collaboration and licensing...

Novavax begins several rolling regulatory reviews for its COVID-19 vaccine
Novavax has started the rolling review process for authorization of its COVID-19 vaccine, NVX-CoV2373, by multiple regulatory agencies.

Novavax to supply Switzerland with 6M doses of COVID-19 vaccine
Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax to produce Canadian supply of COVID-19 vaccine in Canada
Novavax has signed a memorandum of understanding with the Canadian government to produce the company's protein-based COVID-19 vaccine candidate, NVX-CoV2373,...

Novavax COVID-19 vaccine phase III trial indicates up to 89% efficacy
Novavax announced that its protein-based COVID-19 vaccine candidate, NVX-CoV2373, met the primary end point in a U.K. phase III clinical trial, achieving...